Exchange: NASDAQ·Updated 07:37 PM EST
CRBP logo

CRBP Corbus Pharmaceuticals Holdings Inc

$2.09
$0.375
(15.40%)
Today
Closed $2.06
$0.03
(1.46%)
After Hours
Reported EarningsNov 10
Mkt Cap$42.45M
Vol1.38M

About CRBP

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
18

Extremely Bearish Sentiment

How do you feel about CRBP?

h8ster
$CRBP The largest degrossing/money pullout of institutional investors since the covid collapse, of CRBP's niche sector, over the last 6-8 wks, appears to be slowing down and evening out During times of mass volatility, blind selling, and deep AI trading, that doesn't care if the baby goes down the drain with the rest of the dirty bathwater, it's difficult for retail to get an accurate read on any of these plays. My take is that we see V-Shaped recoveries in many of these plays, once oil starts going down. Thats the key to the inflationary fears that started this mess. Inflation is kryptonite for these companies like CRBP. In 2022 JP Morgan said they and other banks will destroy this sector on any inflation fears. The difference between now and then, when they ravaged this sector is that AI has a much larger role, hence the larger damage than in 2022. You can try and guess the bottom or buy on a clear reversal signal The 'babies' will have the best recoveries. CRBP is one of those
6
Notnotshort
$CRBP those institutional holders that were here because of their obesity stuff have sold or greatly reduced already. Those who like their oncology pipeline have bought, which are RA Capital and MPM. RA capital 9,9% owner and MPM 8.6% owner. IMO undervalued here, because RA bought around $6 and MPM also bought way above .
3
Pne01
$CRBP Q&A highlights During questions, Cohen gave more detail. He said the FDA has already aligned with Corbus on the study’s statistical assumptions and efficacy thresholds, though the exact details remain confidential. He said the company is following a Genmab-style strategy: accelerated approval first, then final approval based on survival. He said the study is designed to reflect a real-world oropharyngeal population rather than a narrow HPV-defined group. He said the eye toxicity seen so far is typical of ADCs and usually resolves with standard measures. He said the obesity program drew strong interest because it offers a non-GLP-1 mechanism with a familiar efficacy profile. Cohen also said the second-line oropharyngeal market is especially weak, with limited treatment choices and many patients declining therapy. He framed that as both a medical problem and a business opportunity, while stressing that Corbus still has to deliver the clinical data needed to support its case.
2
birdmine
$CRBP here’s a real question. Does anyone that has been following this stock for a while think that it’s going to break 20$ without a reverse split?
2
Pne01
$CRBP RA capital bought 9,9% of Corbus AFTER the obesity readout 14 sept. MPM BioImpact bought more and reported a 8,6% position AFTER the obesity readout 14 sept. Does this mean they love CRB-913? Maybe not, rather they are in it for CRB-701. They both have an avarage buying price above 7$. No matter how the obesity asset plays out, these two firms belive Corbus is worth way more then 7$. Now we trade under 3$. 2027 will be a great year I'm certain.
1
birdmine
$CRBP I didn’t think that they would actually run this company into the ground!! I was sooo wrong!!!
1
Pne01
$CRBP Always try to stay positive and let the mcap/cash/trials be in the frontseat, but what we see now is a legit freefall. A little concerning I must admit.
1
birdmine
$CRBP earnings is next week, but that shouldn’t make a difference. The Sunday after that kicks off obesity week. Hopefully, it will bring some good news to this trash.
1
LQQKER_INSIDER
$CRBP Down 47% since making this post in May. Someone thought the HC Wainwright $40 price target was legit. 🤣🤣🤣
h8ster
$CRBP Again, this sector is experiencing the worst monetary pullout from Tutes since Covid, since late August. No spec bio company is being spared. In 2022, big bank trading desks told us what they would do to this niche sector if inflation got sticky again. For these companies, it survival of the fittest with the bank's sole intention of destroying as many as possible. They flat out said they'd wipe em all out if possible. The big difference between 2022, when inflation was crazier, is that now they have AI models doing all the work.

Advertisement|Remove ads.